Investors
and Media

Investor Overview

Portola Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Company's first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. Founded in 2003 in South San Francisco, California, Portola has operations in the United States and Europe.

  • Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] was approved by the FDA on May 3, 2018. Learn more.
  • Bevyxxa® (betrixaban) was approved by the FDA on June 23, 2017. Learn more.
  • Cerdulatinib – Investigational, oral, dual-spleen tyrosine kinase (SYK) and janus kinase (JAK) inhibitior. Portola has worldwide rights to develop and commercialize cerdulatinib. Learn more.
Stock Info
NASDAQPTLA
Upcoming Events
No events to display

More ›

Corporate Presentation
Recent News
Aug 22, 2019

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Company will participate in the following conferences in September. Citi's 14th Annual Biotech Conference on Wednesday,...

Aug 13, 2019

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) today announced the pricing of its underwritten public offering of 8,035,715 shares of its common stock at a price to the public of $28.00 per share. In...

Aug 12, 2019

Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. The...

More ›

Annual Report